MedtronicXSWX:MDT +1.21%21 Net Margin % is 12.68% as of Apr. 2026, which is 5% below its 10-year median of 13.38. GuruFocus rates XSWX:MDT with a GF Score™ of 21/100 and a GF Value™ of CHF80.97 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 817 Medical Devices & Instruments companies, Medtronic ranks better than 79.8% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Medtronic's Net Income for the
three
months ended in Apr. 2026 was CHF980 Mil. Medtronic's Revenue for the
three
months ended in Apr. 2026 was CHF7,724 Mil. Therefore, Medtronic's net margin for the quarter that ended in Apr. 2026 was 12.68%.
The historical rank and industry rank for Medtronic's Net Margin % or its related term are showing as below:
XSWX:MDT'
s Net Margin % Range Over the Past 10 Years
Min: 10.36 Med: 13.38 Max: 16.56
Current: 13.2
XSWX:MDT's Net Margin % is ranked better than 79.8% of 817
companies
in the Medical Devices & Instruments industry
Industry Median: 2.07
vs XSWX:MDT: 13.20
Medtronic (XSWX:MDT) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Medtronic Net Margin % Related Terms
Medtronic Net Margin % Historical Data
* Premium members only.
The historical data trend for Medtronic's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Medtronic's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medtronic Net Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Medtronic's Net Margin % distribution charts can be found below:
* The bar in red indicates where Medtronic's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medtronic (XSWX:MDT) has a Net Margin % of 12.68% as of Apr. 2026. Net margin is the ratio of total net income to net sales. View historical data on Medtronic and its competitors. This is near median its historical median of 13.38. Over the past decade, Medtronic's Net Margin % has ranged from 10.36 to 16.56. According to the industry distribution chart, Medtronic ranks #165 out of 817 companies in the Medical Devices & Instruments industry, placing it in the top 20.2%.
Is Medtronic's Net Margin % too high?
Medtronic's current Net Margin % of 12.68% is near median its 10-year median of 13.38. Over the past 10 years, this metric has ranged from a low of 10.36 to a high of 16.56. The Medical Devices & Instruments industry median Net Margin % is 2.07. Medtronic's value of 12.68% is 512.6% above this industry median. Based on the distribution chart, Medtronic ranks #165 out of 817 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Medtronic has a GF Score™ of 21/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medtronic's Net Margin % compare to SYK and BSX?
According to the Medical Devices & Instruments industry distribution chart, Medtronic ranks #165 out of 817 companies for Net Margin %. This places Medtronic in the top 20% of its industry — outperforming the majority of peers. The industry median Net Margin % is 2.07. Medtronic's value of 12.68% is 512.6% above this benchmark. Historically, Medtronic's own Net Margin % has ranged from 10.36 to 16.56 over the past decade. While the company's 10-year median is 13.38 vs. the industry median of 2.07, Medtronic has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Devices & Instruments company?
The median Net Margin % among Medical Devices & Instruments companies is 2.07, based on 817 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medtronic's current Net Margin % of 12.68% is 512.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Medtronic and its competitors. For the Medical Devices & Instruments industry, the median Net Margin % is 2.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medtronic's current Net Margin % is 12.68%, which is near median its own 10-year median of 13.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medtronic stock overvalued right now?
Based on GuruFocus' analysis, Medtronic (XSWX:MDT) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF80.97, compared to a current price of CHF65.29 — trading 19.4% below its estimated fair value. The current Net Margin % is 12.68%, which is near median its 10-year median of 13.38 and 512.6% above the Medical Devices & Instruments industry median of 2.07. Medtronic's overall GF Score™ is 21/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Medtronic (XSWX:MDT), the current Net Margin % is 12.68% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medtronic (XSWX:MDT) Overvalued in 2026?
Based on GuruFocus' analysis, Medtronic stock appears to be undervalued.
The current stock price of CHF65.29 is trading 19.4% below its estimated GF Value™ of CHF80.97.
GuruFocus considers Medtronic to be Modestly Undervalued.
Key valuation signals for XSWX:MDT:
Net Margin %: 12.68% (near median its 10-year median of 13.38)
GF Value™: CHF80.97 vs. price of CHF65.29 (19.4% below fair value)
Industry Position: 512.6% above the Medical Devices & Instruments median (#165 of 817)
No single metric tells the full story. See the XSWX:MDT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, transcatheter heart valves, stents, spinal fixation devices, neurovascular products, advanced energy, ablation laser therapy, and surgical tools. The company primarily markets its products to healthcare institutions and physicians in the United States, Western Europe, and Japan. Foreign sales account for roughly 50% of the company's total sales.
21GF Score
Get the complete analysis for XSWX:MDT
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:MDT has been successfully added to your 
